100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

Vivian Y. Shi, Khiem Tran, Forum Patel, Jonathan Leventhal, Thomas Konia, Maxwell A Fung, Reason Wilken, Miki Shirakawa Garcia, Sarah D. Fitzmaurice, Jayne S Joo, Arta M Monjazeb, Barbara A Burrall, Brett King, Steve Martinez, Scott D Christensen, Emanual Michael Maverakis

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Background Patients with cutaneous melanoma metastases have experienced excellent responses to intralesional interleukin (IL)-2. This has led to its recent inclusion into the US National Comprehensive Cancer Network guidelines for management of cutaneous melanoma metastases. Despite this, intralesional IL-2 has not been highlighted in the US literature nor have US physicians adopted it. Objective We sought to evaluate the effectiveness of intralesional IL-2 combined with topical imiquimod and retinoid for treatment of cutaneous metastatic melanoma. Methods A retrospective case series of 11 patients with cutaneous metastatic melanoma were treated with intralesional IL-2 combined with topical imiquimod and retinoid. Results A 100% complete local response rate with long-term follow-up (average of 24 months) was seen in all 11 patients treated with this proposed regimen. Biopsy specimens of treated sites confirmed absence of malignant cells. The most common treatment-related adverse event was rigors. Limitations Small number of patients, retrospective review of charts, and lack of a comparison group were limitations. Conclusion Intralesional IL-2 administered concomitantly with topical imiquimod and a retinoid cream is a promising therapeutic option for managing cutaneous melanoma metastases. The regimen was well tolerated and should be considered as a reasonable alternative to surgical excision.

Original languageEnglish (US)
Pages (from-to)645-654
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume73
Issue number4
DOIs
StatePublished - Oct 1 2015

Keywords

  • imiquimod
  • interleukin
  • intralesional
  • metastatic melanoma
  • pemphigus vulgaris
  • retinoid

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of '100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series'. Together they form a unique fingerprint.

  • Cite this